Validation of a Multi-gene Test for Lung Cancer Risk
Because more than 160,000 individuals die of lung cancer/year in the United States alone, it
is important to use the best possible methods to determine whether increased surveillance of
individuals at highest risk for lung cancer will result in reduced lung cancer mortality.
The Lung Cancer Risk Test (LCRT) proposed for evaluation promises to accurately identify the
10-15% of the population that is most susceptible to lung cancer based on genetic
predisposition. More than 90 million individuals in the United States alone are
demographically at high risk for lung cancer and potential candidates for increased
surveillance.
Observational
Observational Model: Case-Only, Time Perspective: Prospective
James Willey, MD
Principal Investigator
University of Toledo Health Science Campus
United States: Food and Drug Administration
UTHSC - 11
NCT01130285
May 2011
September 2015
Name | Location |
---|---|
University of Michigan | Ann Arbor, Michigan 48109-0624 |
Cleveland Clinic Foundation | Cleveland, Ohio 44195 |
Mayo Clinic | Rochester, Minnesota 55905 |
Medical University of South Carolina | Charleston, South Carolina 29425-0721 |
Inova Fairfax Hospital | Falls Church, Virginia 22042-3300 |
Ohio State University | Columbus, Ohio 43210 |
The Toledo Hospital | Toledo, Ohio 43606 |
Vanderbilt | Nashville, Tennessee 37212 |
National Jewish Health | Denver, Colorado 80206 |
Henry Ford | Detroit, Michigan 48202 |
University of Toledo, Health Science Campus | Toledo, Ohio 43614 |
Mercy St. Vincent Medical Center | Toledo, Ohio 43608 |
Tennessee Valley Veterans Admin. | Nashville, Tennessee 37232 |